The DiopsysTM NOVA-TR VEP Vision Testing System is an easy-to-operate, non-invasive medical device used to objectively measure neurological responses of the entire visual pathway. The test does not require dilation or sedation. The DiopsysTM NOVA-TR is the only objective visual testing device capable of evaluating the entire visual pathway available today. In addition, currently existing CPT codes enable medical practitioners to be reimbursed for this test.
How it works: After positioning three electrodes on the patients head, an operator initiates the test. Then stimulus is presented to the patient on a video display. The clinician may vary stimulus size, frequency, contrast, time, or eye tested. The results may then be displayed to generate a profile for each eye (displaying responses to several size stimuli), or comparing response to therapy.
The DiopsysTM NOVA-TR system is available in a portable cart point-of-use design.
Why is there a need for DiopsysTM NOVA-TR VEP Testing?
- Provides objective diagnostic data on preverbal children
- Provides objective data on the impact of lenses
- Objective measurement for tracking of treatment efficacy
- Allows diagnosis and enables documentation of issues such as:
- Learning related vision problems
- Contrast sensitivity
- Visual midline shift syndrome (VMSS)
- Post traumatic vision syndrome (PTVS)
- Helps in determination of refractive issues versus amblyopia and can assess sensory loss in amblyopia
- Allows for early detection of amblyogenic factors
Who are we testing and what are we testing for?
We are testing children six months of age and older, patients following a neurological event such as a traumatic brain injury, stroke, or a degenerative process such as multiple sclerosis in order to detect visual deficits such as optic nerve disorders, severe refractive errors, and other problems that could lead to amblyopia, or decreased visual function.
Diopsys NOVA-TR Product Brochure (PDF) |
